Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 2
2009 1
2010 4
2011 6
2012 7
2013 5
2014 6
2015 6
2016 7
2017 6
2018 5
2019 4
2020 3
2021 2
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study.
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Collaro AJ, Chalmers JD, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, Grimwood K. Chang AB, et al. Among authors: hector a. Lancet Respir Med. 2024 Jan;12(1):78-88. doi: 10.1016/S2213-2600(23)00233-3. Epub 2023 Dec 6. Lancet Respir Med. 2024. PMID: 38070531 Review.
Quality standards for managing children and adolescents with bronchiectasis: an international consensus.
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Chalmers JD, Collaro AJ, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, Grimwood K. Chang AB, et al. Among authors: hector a. Breathe (Sheff). 2022 Sep;18(3):220144. doi: 10.1183/20734735.0144-2022. Epub 2022 Nov 15. Breathe (Sheff). 2022. PMID: 36865655 Free PMC article. Review.
Feasibility of unsedated lung MRI in young children with cystic fibrosis.
Willers CC, Frauchiger BS, Stranzinger E, Bauman G, Moeller A, Jung A, Hector A, Regamey N, Zanolari M, Mueller-Suter D, Kuhn AL, Blanchon S, Rochat I, Latzin P, Ramsey KA; the SCILD Study group. Willers CC, et al. Among authors: hector a. Eur Respir J. 2022 Nov 3;60(5):2103112. doi: 10.1183/13993003.03112-2021. Print 2022 Nov. Eur Respir J. 2022. PMID: 36137591 Free article. No abstract available.
Cystic fibrosis related diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicenter trial.
Radtke T, Kriemler S, Stein L, Karila C, Urquhart DS, Orenstein DM, Lands LC, Schindler C, Eber E, Haile SR, Hebestreit H; ACTIVATE-CF Study Working Group. Radtke T, et al. J Cyst Fibros. 2023 Jan;22(1):31-38. doi: 10.1016/j.jcf.2022.06.012. Epub 2022 Jul 6. J Cyst Fibros. 2023. PMID: 35803884
European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials.
Chang AB, Zacharasiewicz A, Goyal V, Boyd J, Alexopoulou E, Aliberti S, Bell L, Bush A, Claydon A, Constant C, Fortescue R, Hill AT, Karadag B, Powell Z, Wilson C, Grimwood K, Kantar A; other members of Child-BEAR-Net; Chalmers J, Collaro A, Douros K, Griese M, Grigg J, Hector A, Mazulov O, Midulla F, Möller A, Proesmans M, Yerkovich S. Chang AB, et al. Among authors: hector a. Eur Respir J. 2022 Nov 3;60(5):2200300. doi: 10.1183/13993003.00300-2022. Print 2022 Nov. Eur Respir J. 2022. PMID: 35728974
International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net.
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Chalmers JD, Collaro AJ, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, Grimwood K. Chang AB, et al. Among authors: hector a. Eur Respir J. 2022 Jun 9;59(6):2200264. doi: 10.1183/13993003.00264-2022. Print 2022 Jun. Eur Respir J. 2022. PMID: 35680151 Free article. No abstract available.
Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).
Hebestreit H, Kriemler S, Schindler C, Stein L, Karila C, Urquhart DS, Orenstein DM, Lands LC, Schaeff J, Eber E, Radtke T; ACTIVATE-CF Study Working Group. Hebestreit H, et al. Am J Respir Crit Care Med. 2022 Feb 1;205(3):330-339. doi: 10.1164/rccm.202106-1419OC. Am J Respir Crit Care Med. 2022. PMID: 34735776 Free PMC article. Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
61 results